2009;169:832 42. S9.7-11. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical out- comes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008;31:353 60. S9.7-12. Laurent S, Boutouyrie P; Vascular Mechanism Collaboration. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension. 2014;64:709 16. S9.7-13. Reisin E, Owen J. Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection. J Am Soc Hypertens. 2015;9:156 59; quiz 160. 9.8. Atrial Fibrillation S9.8-1. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832 9. S9.8-2. Zhao D, Wang Z-M, Wang L-S. Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res. 2015;29:475 85. S9.8-3. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol. 2004;44:109 16. S9.8-4. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199 267. S9.8-5. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0 1: a nation- wide cohort study. Thromb Haemost. 2012;107:1172 9. S9.8-6. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a caus- ative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003;91:9G 14G. S9.8-7. 